Chime Biologics has inked a strategic partnership with Waterstone, aimed at providing integrated services for Antibody-Drug Conjugate (ADC) industry worldwide.

Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.

Leveraging its CMC expertise in biologics, Chime Biologics will manage Antibody Intermediate, ADC Drug Substance and Drug Product process development and cGMP manufacturing.  Waterstone will supply Linker-payload, a critical intermediate in the ADC manufacturing process.

Dr. Faming Zhang, CEO of Waterstone commented, "Our partnership with Chime Biologics is a significant milestone for Waterstone. Their expertise in antibody drug development and GMP manufacturing will be instrumental as we expand into global markets and advance our assets. We are excited about this collaboration, which provides a bright future for our company and the broader ADC industry."

Dr. Jimmy Wei, President of Chime Biologics, added, "We are thrilled to embark on this strategic collaboration with Waterstone. Currently, Chime Biologics has begun to undertake multiple ADC projects. This partnership will significantly advance our innovation and growth in the ADC field. We look forward to exploring the boundless possibilities of ADC together with Waterstone."